TY - JOUR
T1 - Clinical and prognostic features of patients with philadelphia chromosome‐positive chronic myelogenous leukemia and extramedullary disease
AU - Terjanian, Terenig
AU - Kantarjian, Hagop
AU - Keating, Michael
AU - Talpaz, Moshe
AU - McCredie, Kenneth
AU - Freireich, Emil J.
PY - 1987/1/15
Y1 - 1987/1/15
N2 - Twenty‐four patients who developed extramedullary disease during the course of Philadelphia chromosomepositive chronic myelogenous leukemia are described. The most frequent sites of extramedullary disease were lymph nodes (54%), bone (37%), and skin and soft tissue (29%). The appearance of extramedullary disease was associated with a high incidence of other features of accelerated disease (37%) and with cytogenetic clonal evolution (62.5%). The median time from extramedullary disease to blastic crisis was 4 months, and the median survival was 5 months. At the time of analysis, 23 patients have died, 16 after evolving into blastic crisis, and 7 from progressive disease without satisfying the criteria of medullary blastic crisis. This study confirms the importance of extramedullary disease as a sign of poor prognosis in chronic myelogenous leukemia, and the need for alternate therapies when such an event develops. Cancer 59:297–300, 1987.
AB - Twenty‐four patients who developed extramedullary disease during the course of Philadelphia chromosomepositive chronic myelogenous leukemia are described. The most frequent sites of extramedullary disease were lymph nodes (54%), bone (37%), and skin and soft tissue (29%). The appearance of extramedullary disease was associated with a high incidence of other features of accelerated disease (37%) and with cytogenetic clonal evolution (62.5%). The median time from extramedullary disease to blastic crisis was 4 months, and the median survival was 5 months. At the time of analysis, 23 patients have died, 16 after evolving into blastic crisis, and 7 from progressive disease without satisfying the criteria of medullary blastic crisis. This study confirms the importance of extramedullary disease as a sign of poor prognosis in chronic myelogenous leukemia, and the need for alternate therapies when such an event develops. Cancer 59:297–300, 1987.
UR - http://www.scopus.com/inward/record.url?scp=0023108166&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023108166&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19870115)59:2<297::AID-CNCR2820590221>3.0.CO;2-B
DO - 10.1002/1097-0142(19870115)59:2<297::AID-CNCR2820590221>3.0.CO;2-B
M3 - Article
C2 - 3467820
AN - SCOPUS:0023108166
SN - 0008-543X
VL - 59
SP - 297
EP - 300
JO - Cancer
JF - Cancer
IS - 2
ER -